c-Abl mediates angiotensin II-induced apoptosis in podocytes

Xinghua Chen1, Zhilong Ren, Wei Liang

  • 1Division of Nephrology, Renmin Hospital of Wuhan University, 238 Jiefang Rd, Wuhan, 430060, Hubei, China.

Insights

Angiotensin II (Ang II) triggers podocyte apoptosis via the nonreceptor tyrosine kinase c-Abl. Inhibiting c-Abl protects podocytes from Ang II-induced injury, suggesting a therapeutic target for kidney disease.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Biology

Background:

  • Angiotensin II (Ang II) is implicated in podocyte apoptosis, but the underlying mechanisms remain unclear.
  • Podocyte injury is a key factor in the progression of various kidney diseases.

Purpose of the Study:

  • To investigate the role of the nonreceptor tyrosine kinase c-Abl in Angiotensin II-induced podocyte apoptosis.
  • To explore potential therapeutic strategies targeting c-Abl for podocyte protection.

Main Methods:

  • In vivo studies involved administering Ang II to rats with or without a c-Abl inhibitor (STI-571).
  • In vitro studies utilized cultured mouse podocytes treated with Ang II and various c-Abl modulators (inhibitor, siRNA, plasmid).
  • Podocyte apoptosis was assessed using TUNEL staining, transmission electron microscopy, flow cytometry, and Hoechst staining. c-Abl expression and activity were measured by qPCR, Western blotting, and immunofluorescence.

Main Results:

  • Ang II administration increased c-Abl expression and phosphorylation in rat glomeruli and cultured podocytes.
  • Ang II upregulated nuclear c-Abl and p53 protein, forming complexes and promoting podocyte apoptosis.
  • Inhibition of c-Abl by STI-571 or siRNA attenuated Ang II-induced podocyte apoptosis, while c-Abl overexpression enhanced it.

Conclusions:

  • The nonreceptor tyrosine kinase c-Abl mediates Angiotensin II-induced podocyte apoptosis.
  • Inhibition of c-Abl expression offers a protective effect against Ang II-induced podocyte injury.
  • Targeting c-Abl presents a potential therapeutic avenue for managing Ang II-related kidney damage.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...